The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes
Reads0
Chats0
TLDR
PIs have been recently proven to also be efficacious in blocking MM-induced osteocyte death providing new possible therapeutic use in the management of bone loss, and the conjugation of PIs with bisphosphonates showed good results in terms of bone anabolic activity.Abstract:
The alterations of bone remodeling are typical of multiple myeloma (MM) patients where the uncoupled and unbalanced bone remodeling caused the onset of osteolytic lesions. Moreover, bone metastasis occurs in the majority of patients with breast and prostate cancer. Skeletal-related events negatively impact on quality of life by increasing the vulnerability to fractures. Several bone-targeting treatments have been developed to control bone pain and pathological fractures, including bisphosphonates and Denosumab. Nevertheless, these agents act by inhibiting osteoclast activity but do not improve bone formation. Proteasome inhibitors (PIs) have shown bone anabolic effects and encouraging results in stimulating osteoblast differentiation and bone healing. Among these, the first-in-class bortezomib and the second-generation PIs, carfilzomib, and ixazomib regulate the bone remodeling process by controlling the degradation of several bone proteins. PIs have been recently proven to also be efficacious in blocking MM-induced osteocyte death providing new possible therapeutic use in the management of bone loss. PIs have significant side effects that limit their use as bone anabolic strategy. Multiple alternative approaches have been made. The conjugation of PIs with bisphosphonates, which can target them to bone, showed good results in terms of bone anabolic activity. However, the clinical implications of these effects require further investigations.read more
Citations
More filters
Journal ArticleDOI
Mechanisms, Diagnosis and Treatment of Bone Metastases
TL;DR: In this paper, the role of the bone marrow microenvironment in the attraction, homing, dormancy and outgrowth of metastatic tumor cells and the ensuing therapeutic implications is discussed.
Therapeutic targets in myeloma bone disease
TL;DR: In this paper, the authors discuss the mechanisms regulating the uncoupled bone remodelling in multiple myeloma (MM) and summarizes current advances in the treatment of MBD, including antiresorptive agents that are only partially effective due to their inability to repair the existing lesions.
Journal ArticleDOI
N-Heterocycle derivatives: An update on the biological activity in correlation with computational predictions
Sahar Saleh Alghamdi,Rasha Saad Suliman,Rawan Awadh Alshehri,Razan Suleiman Almahmoud,Renad Ibrahim Alhujirey +4 more
TL;DR: The selected N-heterocycle derivatives possess promising medicinal properties that could be utilized for future drug discovery, including oxazolone, oxazole, and oxadiazole.
References
More filters
Journal ArticleDOI
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21Cip1 and p27Kip1.
Dan Zhang,Rong Fan,Li Lei,Lei Lei,Yanmeng Wang,Nan Lv,Ping Chen,Ramone A. Williamson,Baiyan Wang,Jinsong Hu +9 more
TL;DR: An intracellular pathway that integrates proteasome inhibition, osteogenic differentiation and the cell cycle through activation of the ER stress signalling branch Ire1α/Xbp1s is revealed.
Journal ArticleDOI
Local application of a proteasome inhibitor enhances fracture healing in rats.
Toshitaka Yoshii,Toshitaka Yoshii,Jeffry S. Nyman,Masato Yuasa,Masato Yuasa,Javier Esparza,Atsushi Okawa,Gloria Gutierrez,Gloria Gutierrez +8 more
TL;DR: The local administration of PSI in vivo promoted fracture healing in rats, as demonstrated by an increased fracture callus volume in radiographs at 2 weeks post‐fracture, and improved radiographic scores.
Journal ArticleDOI
Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation
Seira Hoshikawa,Kouhei Shimizu,Asami Watahiki,Mitsuki Chiba,Kan Saito,Wenyi Wei,Satoshi Fukumoto,Satoshi Fukumoto,Hiroyuki Inuzuka +8 more
TL;DR: The molecular mechanisms underlying the Osx protein stability control are unveiled and it is suggested that targeting the OsX degradation pathway could help enhance efficient osteogenesis and bone matrix regeneration.
Journal ArticleDOI
The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease
R J Ma,S W Yang,X L Yuan,L Jiang,Jin-Ji Yang,Z Wang,Youyi Zhang,P C Lei,L. Zhang,B J Shang,L N Cheng,Z M Zhu +11 more
TL;DR: After treatment with the proteasome inhibitor -based regimen, the serum concentrations of TRACP-5b, β-CTX and vitamin D3, which reflect osteoclast activity in MBD patients were decreased, the Serum concentration of PINP indicating osteoblast activity was increased, and the grade of imaging of bone disease was decreased.